Sepracor Seeks FDA Nod For Long-Acting Beta Agonist Arformoterol
This article was originally published in The Pink Sheet Daily
Executive Summary
User fee date for the chronic obstructive pulmonary disease agent would fall in October, assuming a standard 10-month review.